Policy Notices

• Notice of Expiration - PA-21-158, "Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33) - Clinical Trial Optional"
  (NOT-HS-21-008)
  Agency for Healthcare Research and Quality
  

• UPDATE Implementation of Requirement to Submit the Federal Financial Report (FFR) in the Payment Management System
  (NOT-OD-21-060)
  National Institutes of Health
  

General Notices

• Reminder Requesting Extensions for Early Career Scientists Whose Career Trajectories Have Been Significantly Impacted by COVID-19
  (NOT-OD-21-052)
  National Institutes of Health
  

• Request for Information (RFI): Use of Common Data Elements (CDEs) in NIH-funded research
  (NOT-LM-21-005)
  National Library of Medicine
  National Institute of Neurological Disorders and Stroke
  

• Request for Information on the 2021-2026 National Institute of Neurological Disorders and Stroke Strategic Plan
  (NOT-NS-21-021)
  National Institute of Neurological Disorders and Stroke
  

• Request for Information (RFI): Screening for High Resolution Cryo-Electron Microscopy
  (NOT-RM-21-012)
  Office of Strategic Coordination (Common Fund)
  

Notice of Changes to Funding Opportunities

• Notice to Extend the Expiration Date for PAR-19-222, "Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21 Clinical Trial Optional)"
  (NOT-DK-21-011)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to Key Dates of PAR-20-286, "Practice-Based Suicide Prevention Research Centers (P50 Clinical Trial Optional)"
  (NOT-MH-21-160)
  National Institute of Mental Health
  

• Notice of Change to Key Dates for PA-18-622 "Disease Mechanisms of Prenatal and Pediatric Hydrocephalus (R01 Clinical Trial Not Allowed)"
  (NOT-NS-21-027)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Key Dates for PA-18-623 "Tools to Enhance the Study of Prenatal and Pediatric Hydrocephalus (R21 Clinical Trial Not Allowed)"
  (NOT-NS-21-028)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Correction to PAR-20-256: Clarification on Frequency of Usage Reports
  (NOT-OD-21-048)
  National Institutes of Health
  

• Notice to Extend the Expiration Date for PA-18-590 Change of Grantee Organization (Type 7 Parent Clinical Trial Optional)
  (NOT-OD-21-054)
  National Institutes of Health
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Human Milk as a Biological System (R01 Clinical Trial Optional)
  (NOT-HD-21-005)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)
  (NOT-AI-21-008)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control
  (NOT-CA-21-033)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations with the NCI-supported Drug Resistance and Sensitivity Network (DRSN)
  (NOT-CA-21-034)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19
  (NOT-DA-21-017)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders
  (NOT-DA-21-018)
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Urgent Competitive Revisions and Administrative Supplements for Research at NIMHD Research Centers in Minority Institutions (RCMI U54s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation
  (NOT-MD-21-012)
  National Institute on Minority Health and Health Disparities
  

• Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs
  (NOT-TR-21-017)
  National Center for Advancing Translational Sciences
  

Funding Opportunities

• Using Innovative Digital Healthcare Solutions to Improve Quality at the Point of Care (R21/R33 - Clinical Trial Optional)
  (PA-21-158)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): Standard dates apply. All applications are due by 5:00 PM local time of the applicant organization
  
  

• Limited Competition for the Continuation of Multisite Clinical Trial Data Coordinating Center (Collaborative U24 Clinical Trial Optional)
  (PAR-21-116)
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): March 15, 2021; May 28, 2021; September 28, 2021; January 28, 2022; May 27, 2022; September 28, 2022; January 27, 2023; May 29, 2023; September 27, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Limited Competition for the Continuation or Revision of Multisite Clinical Trial Clinical Coordinating Center (Collaborative UH3 Clinical Trial Optional)
  (PAR-21-117)
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): March 15, 2021; May 28, 2021; September 28, 2021; January 28, 2022; May 27, 2022; September 28, 2022; January 27, 2023; May 29, 2023; September 28, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)
  (PAR-21-144)
  NIH Basic Behavioral and Social Science Opportunity Network
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): March 17, 2021
  
  

• Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Clinical Trials Not Allowed)
  (PAR-21-145)
  NIH Basic Behavioral and Social Science Opportunity Network
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): March 17, 2021
  
  

• SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)
  (RFA-AA-21-002)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)
  (RFA-AA-21-003)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)
  (RFA-AA-21-004)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Early-Phase Clinical Trials of Novel Interventions to Prevent, Delay, or Treat Aging-Related Conditions by Targeting Aging-Related Mechanisms (U01 Clinical Trial Required)
  (RFA-AG-22-011)
  National Institute on Aging
  Application Receipt Date(s): June 17, 2021
  
  

• Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)
  (RFA-DA-22-004)
  National Institute on Drug Abuse
  Application Receipt Date(s): Not Applicable
  
  

• High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed)
  (RFA-DA-22-006)
  National Institute on Drug Abuse
  Application Receipt Date(s): September 15, 2021
  
  

• Screening for Conditions by Electronic Nose Technology (SCENT) (U01 Clinical Trial Optional)
  (RFA-TR-21-009)
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): June 10, 2021